BioMarin Pharma (BMRN): BMN-270 Update Is An Incremental Positive - Baird
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Baird analyst, Michael Ulz, reiterated his Outperform on shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) on the heels of the BMN-270 update which he views as an incremental positive.
After the close, BioMarin announced that UK regulators approved continued enrollment in the Phase 1/2 study of BMN-270 (gene therapy) in Hemophilia A. Importantly, continuation indicates regulators are not overly concerned with Factor VIII expression above the normal range (two patients >150%) or ALT elevations. Additionally, the study was amended to allow dose optimization ahead of the Phase 2b study expected to begin in 2H17.
The analyst is encouraged these updates and reiterated his Outperform rating.
No change to the price target of $115.
Shares of BioMarin Pharmaceutical Inc. closed at $86.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gabelli Starts BioMarin Pharmaceutical Inc. (BMRN) at Buy
- Broadcom (AVGO) PT Raised to $210 at Mizuho
- FBR Capital Raises Price Target on Methode Electronics (MEI) Following Better Than Expected 2Q
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!